Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association
sickle cell anaemia is :: Article Creator Upcoming Phase 2a Trial To Test Oral Desidustat In Sickle Cell Disease Zydus Lifesciences is launching a proof-of-concept Phase 2a clinical trial to evaluate the safety and efficacy of its oral candidate desidustat in people with sickle cell disease (SCD). The study is the result of a collaboration with the Indian Council of Medical Research (ICMR). "Public-private partnerships in the healthcare sector is essential to deliver novel [drugs] to achieve the goals of the National Sickle Cell Anaemia Elimination Mission," Pankaj Patel, chairman of Zydus, said in a company press release. "The initiation of this study reaffirms hope for the 20 million sickle cell-affected patients in the country for a high potential novel treatment." Desidustat is approved in India under the name Oxemia for treating people with anemia, or a shortage of red blood cells, associated with chronic kidney diseas